HomeGenzyme CorporationBuscaFale ConoscoWebsites da Genzyme
Informação CorporativaNossas Áreas de TratamentoNossos ProdutosÍndice Médico
Genzyme

Informação Corporativa
Genzyme do Brasil
Nossos Negócios
Cargos & Benefícios
Notícias da Genzyme
Todas as Notícias da Genzyme
Eventos
A Genzyme no Mundo
Pesquisa e Desenvolvimento

Notícias da Genzyme

Genzyme
August 25, 2008Genzyme Corporation and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics to Accelerate Discovery of Novel Therapies for Malaria
August 6, 2008Genzyme and Isis Begin Second Phase 3 Trial of Mipomersen
July 23, 2008Genzyme Reports Strong Second-Quarter Growth
July 17, 2008Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
June 24, 2008Genzyme and Isis complete licensing of mipomersen
June 17, 2008Genzyme Files Applications for Approval of Mozobil in the United States and Europe
June 2, 2008Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
May 7, 2008Preliminary Results from Phase 2 Genzyme Study
April 25, 2008FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
April 23, 2008Genzyme Reports Strong First-Quarter Growth
April 22, 2008Genzyme to Build New R&D Center in Beijing
April 21, 2008Genzyme Provides Update on Myozyme® Manufacturing
April 14, 2008Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
March 19, 2008Genzyme Withdraws Bioenvision’s European Filing of Evoltra® in Elderly AML Patients
March 10, 2008Genzyme Announces Presentation of New Positive Data on Carticel®
March 6, 2008Genzyme Launches Renvela® in the U.S. for Dialysis Patients
February 13, 2008Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
February 1, 2008University of Massachusetts and Genzyme Launch Genzyme/UMass Scholars Program
February 1, 2008Genzyme and Isis Announce Hart-Scott-Rodino Approval Of Collaboration
January 15, 2008Genzyme Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Lung Cancer Diagnostic
January 8, 2008Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue
January 7, 2008Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
December 19, 2007Genzyme Receives European CE Mark for Single-Treatment Synvisc-One™
December 17, 2007Genzyme Announces FDA Approval of Thyrogen® For Use In Thyroid Cancer Ablation
December 13, 2007Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
December 5, 2007Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
December 4, 2007National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment
November 13, 2007Genzyme Receives FDA Response Letter on Synvisc-One™
October 29, 2007Epicel™ Wins Marketing Approval for Severe Burn Victims
October 25, 2007Genzyme and Sunway to Collaborate on Gene Therapy Program in China
October 24, 2007Genzyme Reports Strong Earnings Growth in Third Quarter
October 23, 2007Genzyme Launches Cholestagel® in Europe
October 22, 2007Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
October 22, 2007FDA Approves Genzyme's Renvela for Dialysis Patients
October 16, 2007Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
October 15, 2007Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
October 12, 2007Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
October 12, 2007Genzyme Recognized by Scientists as a Top Employer
October 10, 2007Delaware Court Approves Bioenvision, Genzyme Joint Petition
October 10, 2007Bioenvision and Genzyme File Petition in Delaware Court
October 4, 2007Genzyme Receives Approval to Market Elaprase® in Japan
September 27, 2007Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
September 26, 2007Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
September 20, 2007FDA Approves Expanded Labeling for Campath® to Include First-line Treatment for Leading Form of Adult Leukemia
September 18, 2007Genzyme Begins Major Expansion of Boston Manufacturing Facility
August 29, 2007Genzyme Announces Publication of DCOR Study in Kidney International
July 23, 2007Oswaldo Cruz Foundation and Genzyme Corporation Form Collaboration To Advance New Drugs for Neglected Diseases



INFORMAÇÕES DE CONTATO:
Genzyme do Brasil Ltda.
São Paulo
Av. Francisco Matarazzo, 1400
10º andar - Conj. 101 - Edifício Milano
Água Branca
05001-903 - São Paulo – SP
SAC: 0800 77 123 73
Tel: +55 (11) 3874-9950
Fax: +55 (11) 3874-9952

São Paulo
Rua Padre Chico, 224
Vila Pompéia
05008 - 010 - São Paulo – SP
Tel: +55 (11) 3872-5761

Rio de Janeiro
Praça Floriano, 19 - 26º andar – Centro
20031-050 - Rio de Janeiro – RJ
Tel: +55 (21) 2156-9950
Fax: +55 (21) 2156-9952

Envie-nos um email


Genzyme de Argentina S.A.
Fondo de la Legua 161
(B1609JEB) Boulogne,
Provincia de Buenos Aires,
Argentina
T: + 54 11 4708-6900
F: + 54 11 4700-8111
www.genzyme.com.ar

Genzyme Chile Ltda.
Santiago de Chile
T: + 54 11 4708-6900
www.genzyme.cl

Genzyme de Colombia S. A.
Calle 93 B #17–25/49, Piso 5
Bogotá, Colombia
T: + 57 1 621 6600
F: + 57 1 621 6677
www.genzyme.com.co

Genzyme México S. de R.L. de C.V.
Paseo de la Reforma 505
Piso 49 Col. Cuauhtémoc
México Distrito Federal, C.P. 06500
México
T: + 52 55 5241 0600
F: + 52 55 5241 0659
www.genzyme.com.mx

Termos e Condições de Uso | Política de Privacidade | © 2003-2008 Genzyme Corporation. Todos os direitos reservados.